证券日报网讯1月30日，祥生医疗在互动平台回答投资者提问时表示，公司销售模式包括经销和直销两 种模式，经销业务为主，直销业务为辅，其中直销业务以ODM为主，面向终端的直销较少，目前公司 产品和技术已进入包括欧美市场在内的全球100多个国家和地区。 ...

Core Viewpoint - The company DaAn Gene expects a net profit attributable to shareholders of between -865 million to -607 million yuan for 2025, an improvement from -925 million yuan in the same period last year [1] Financial Performance - The expected net profit after deducting non-recurring items is projected to be between -938 million to -658 million yuan, compared to -823 million yuan in the previous year [1] - The performance fluctuation is primarily due to decreased revenue from market demand, centralized procurement policies, and tax rate adjustments, leading to operational losses [1] Investment and Asset Management - Improved performance from joint ventures has resulted in increased investment income [1] - The company has strengthened the collection of accounts receivable, leading to a reduction in related credit impairment losses, although asset impairment losses have increased [1] - The fair value of other non-current financial assets has risen, with non-recurring gains before tax increasing by approximately 180 million yuan [1]

Core Viewpoint - Aomei Medical (002950) is expected to report a significant decline in net profit for the year 2025, with projections indicating a decrease of 30.16% to 41.55% compared to the previous year [1] Financial Performance - The projected net profit for 2025 is estimated to be between 216 million yuan and 258 million yuan [1] - The net profit excluding non-recurring gains and losses is forecasted to be between 180 million yuan and 222 million yuan, reflecting a year-on-year decline of 35.49% to 47.72% [1]

Core Viewpoint - Yuyue Medical announced that its subsidiary, Pumeikang (Jiangsu) Medical Technology Co., Ltd., has received a medical device registration certificate for a semi-automatic external defibrillator from the National Medical Products Administration [1] Group 1 - The product is named semi-automatic external defibrillator and is classified as Class III medical device [1] - The registration certificate number is Guo Xie Zhu Ren 20263080239, with a validity period from January 29, 2026, to January 28, 2031 [1] - The device provides voice/animation guidance for cardiopulmonary resuscitation and prompts users for external defibrillation treatment, aimed at treating suspected cardiac arrest patients who are unresponsive, not breathing or have abnormal breathing, and show no signs of circulation [1]

南财智讯1月30日电，鱼跃医疗公告，控股孙公司普美康（江苏）医疗科技有限公司收到国家药品监督 管理局颁发的半自动体外除颤器《医疗器械注册证》，产品适用于救治无反应、无呼吸或呼吸不正常、 无循环迹象的疑似心脏骤停患者，其中成人模式适用于8岁及以上或体重25kg及以上的患者，儿童模式 适用于8岁以下或体重25kg以下的患者；该产品在公共场所、家庭、医疗场所、转运过程中以及携带到 紧急事件现场使用，应由接受过心肺复苏和自动体外除颤器使用培训合格的人员使用，或者在急救中心 调度人员指导下使用，或者由接受过基本生命支持和高级生命支持课程培训合格的医务人员使用。本次 获批有利于提升公司在急救领域的技术实力和市场竞争力，助推急救板块业务发展。相关产品未来销售 情况受行业政策、市场需求及市场竞争环境等因素影响，对公司业绩的影响尚具有不确定性。 ...

Core Viewpoint - The company, 亚辉龙 (688575.SH), expects a significant decline in net profit for the fiscal year 2025, projecting a decrease of 90.05% to 93.37% compared to the previous year [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is estimated to be between 20 million to 30 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between 65 million to 85 million yuan, reflecting a year-on-year decrease of 70.42% to 77.38% [1] Market Conditions - The company anticipates a reduction in domestic market demand in the short term due to industry policy impacts, which is expected to lead to a decline in both revenue and gross margin compared to the previous year [1] Asset Management - The company has reported a loss due to fair value changes in its trading financial assets, specifically related to its holdings in 云康集团有限公司 (02325.HK) [1] - In accordance with the "Enterprise Accounting Standards" and related regulations, the company plans to recognize and test impairment indicators for its assets as of December 31, 2025, and intends to make provisions for asset impairments [1]

2025年度，受行业政策影响，短期国内市场需求减少,公司本期营业收入以及毛利率较上年同期下降， 导致本期实现的营业毛利额较上年同期有所下降。此外，公司持有的交易性金融资产（云康集团有限公 司(02325.HK)的股票）因公允价值变动产生亏损。另外，根据《企业会计准则》等相关规定，基于谨慎 性原则，公司对截至2025年12月31日的各项资产进行了减值迹象的识别和测试，拟计提相关资产的减值 准备。 格隆汇1月30日丨亚辉龙(688575.SH)公布，预计2025年度实现归属于母公司所有者的净利润为2,000.00 万元至3,000.00万元，同比减少90.05%至93.37%。预计2025年度实现归属于母公司所有者的扣除非经常 性损益的净利润6,500.00万元至8,500.00万元，同比减少70.42%至77.38%。 ...

南财智讯1月30日电，蓝帆医疗发布2025年年度业绩预告，预计2025年全年归属于上市公司股东的净利 润为亏损6.50亿元—8.50亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏 损7.80亿元—9.80亿元。2025年由于下述主要原因综合作用，导致公司年度业绩出现波动：1、受国际贸 易形势影响，公司健康防护事业部2025年订单形势波动，同时叠加销售价格承压，尽管2025年第四季度 毛利率已回正，但全年仍呈现明显亏损。此外：①公司健康防护事业部相关主体根据税务部门要求就 2020年度至2022年度跨境关联交易转让定价相关涉税事项开展特别纳税调整自查而产生补缴税款及加收 利息事项，详见公司与本公告同日披露的《关于补缴税款的公告》（公告编号：2026-011），②公司依 据业务及市场情况对健康防护事业部固定资产进行合理减值及报废，以上两项均对健康防护事业部2025 年度净利润有明显负向影响。2、公司心脑血管事业部子公司参股投资的苏州同心医疗科技股份有限公 司（以下简称"苏州同心"）于2025年6月底完成上市前融资，其一级市场估值变动造成公司其他非流动 金融资产确认公允价值变动损失约1.2 ...

Core Viewpoint - Jiuan Medical (002432.SZ) is expected to achieve a net profit of 2.02 billion to 2.35 billion yuan in 2025, representing a year-on-year growth of 21.05% to 40.83% primarily driven by strong performance in asset management business [1][13]. Financial Performance - For the first three quarters of 2025, Jiuan Medical reported revenue of 1.069 billion yuan, but net profit reached 1.589 billion yuan, with total operating costs exceeding revenue at 1.276 billion yuan [3][15]. - Investment income for the same period was 562 million yuan, and fair value changes contributed 1.251 billion yuan, totaling over 1.8 billion yuan in income from these sources [3][15]. - The company’s net profit attributable to shareholders is projected to grow by 21.05% to 40.83% compared to the previous year [2][14]. Asset Management - As of the end of Q3 2025, Jiuan Medical held trading financial assets worth 10.362 billion yuan, primarily in wealth management products, along with fixed-income securities and equity investments totaling 13.877 billion yuan [4][16]. - The total assets under management reached 24.122 billion yuan, indicating a significant contribution from asset management to overall profitability [5][18]. Product Performance - The iHealth product line, which includes smart medical devices, has seen a significant decline in revenue, with a 50% drop in the first half of 2025 compared to the previous year [8][21]. - Overall revenue from the iHealth series decreased by 49% in the first three quarters of 2025 [9][20]. Market Position - Jiuan Medical's price-to-book (PB) ratio is currently at 0.89, indicating it is trading below its book value [11][23]. - The company has substantial cash-like assets totaling 27.6 billion yuan, with short-term borrowings of only 2.334 billion yuan, suggesting a strong liquidity position [11][23].

以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 资料显示，公司主营POCT试剂及仪器。 中证智能财讯安旭生物（688075）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润7100万元至8500万元，同比下降55.8%-63.08%；扣非净利润 预计1300万元-1560万元，同比下降58.84%-65.7%。以1月30日收盘价计算，安旭生物目前市盈率（TTM）约为60.16倍-72.03倍，市净率（LF）约0.99倍，市 销率（TTM）约11.05倍。 此外，美国政府加征关税使得部分区域市场订单减少，公司承担部分关税导致营业成本上升，加上汇率波动引起汇兑损失、利息收入降低及资产折旧摊销等 多方面原因导致利润同比下滑。 指标注解： 据公告，公司业绩变动原因为， 报告期内，公司主营业务保持稳健发展，为巩固在产业领域内的长期竞争优势，公司保持原有几大技术平台的先进性之 外，持续加大对新技术平台的战略性投入，同时国内外市场及注册证书等拓展，海外分子公司的布局致使费用增加。 市盈率=总市值/净利润。当公司亏损时市盈率为负，此时用市盈率估值没有实际意义，往往用市净率或市销率做参考。 市 ...